Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 697

1.

Vaccines and global health: In search of a sustainable model for vaccine development and delivery.

Rappuoli R, Black S, Bloom DE.

Sci Transl Med. 2019 Jun 19;11(497). pii: eaaw2888. doi: 10.1126/scitranslmed.aaw2888. Review.

PMID:
31217336
2.

TIPICO IX: report of the 9th interactive infectious disease workshop on infectious diseases and vaccines.

Martinón-Torres F, Bosch X, Rappuoli R, Ladhani S, Redondo E, Vesikari T, García-Sastre A, Rivero-Calle I, Gómez-Rial J, Salas A, Martín C, Finn A, Butler R.

Hum Vaccin Immunother. 2019 Jun 3:1-11. doi: 10.1080/21645515.2019.1609823. [Epub ahead of print]

PMID:
31158041
3.

Transmission-Blocking Vaccines for Malaria: Time to Talk about Vaccine Introduction.

Coelho CH, Rappuoli R, Hotez PJ, Duffy PE.

Trends Parasitol. 2019 May 29. pii: S1471-4922(19)30084-4. doi: 10.1016/j.pt.2019.04.008. [Epub ahead of print]

PMID:
31153722
4.

Towards animal free and science based measures of critical quality attributes for vaccine quality control and release.

Rappuoli R.

Vaccine. 2019 Jun 27;37(29):3745-3746. doi: 10.1016/j.vaccine.2019.05.039. No abstract available.

PMID:
31151803
5.

Safety of AS03-adjuvanted influenza vaccines: A review of the evidence.

Cohet C, van der Most R, Bauchau V, Bekkat-Berkani R, Doherty TM, Schuind A, Tavares Da Silva F, Rappuoli R, Garçon N, Innis BL.

Vaccine. 2019 May 21;37(23):3006-3021. doi: 10.1016/j.vaccine.2019.04.048. Epub 2019 Apr 25. Review.

6.

Self-Assembling Nanoparticles Usher in a New Era of Vaccine Design.

Rappuoli R, Serruto D.

Cell. 2019 Mar 7;176(6):1245-1247. doi: 10.1016/j.cell.2019.02.008.

PMID:
30849370
7.

Comparison of Open-Source Reverse Vaccinology Programs for Bacterial Vaccine Antigen Discovery.

Dalsass M, Brozzi A, Medini D, Rappuoli R.

Front Immunol. 2019 Feb 14;10:113. doi: 10.3389/fimmu.2019.00113. eCollection 2019. Review.

8.

Post-hoc analysis from phase III trials of human papillomavirus vaccines: considerations on impact on non-vaccine types.

Ryser M, Berlaimont V, Karkada N, Mihalyi A, Rappuoli R, van der Most R.

Expert Rev Vaccines. 2019 Mar;18(3):309-322. doi: 10.1080/14760584.2019.1579647. Epub 2019 Mar 4.

PMID:
30739514
9.

Inhibiting neuraminidase can make the difference.

Rappuoli R, Del Giudice G.

J Exp Med. 2019 Feb 4;216(2):251-252. doi: 10.1084/jem.20182245. Epub 2019 Jan 25.

PMID:
30683738
10.

Genetic Meningococcal Antigen Typing System (gMATS): A genotyping tool that predicts 4CMenB strain coverage worldwide.

Muzzi A, Brozzi A, Serino L, Bodini M, Abad R, Caugant D, Comanducci M, Lemos AP, Gorla MC, Křížová P, Mikula C, Mulhall R, Nissen M, Nohynek H, Simões MJ, Skoczyńska A, Stefanelli P, Taha MK, Toropainen M, Tzanakaki G, Vadivelu-Pechai K, Watson P, Vazquez JA, Rajam G, Rappuoli R, Borrow R, Medini D.

Vaccine. 2019 Feb 8;37(7):991-1000. doi: 10.1016/j.vaccine.2018.12.061. Epub 2019 Jan 17.

11.

On the mechanisms of conjugate vaccines.

Rappuoli R, De Gregorio E, Costantino P.

Proc Natl Acad Sci U S A. 2019 Jan 2;116(1):14-16. doi: 10.1073/pnas.1819612116. Epub 2018 Dec 21. No abstract available.

PMID:
30578318
12.

Vaccine candidates for poor nations are going to waste.

Kaslow DC, Black S, Bloom DE, Datla M, Salisbury D, Rappuoli R.

Nature. 2018 Dec;564(7736):337-339. doi: 10.1038/d41586-018-07758-3. No abstract available.

PMID:
30560957
13.

Antimicrobial resistance and the role of vaccines.

Bloom DE, Black S, Salisbury D, Rappuoli R.

Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12868-12871. doi: 10.1073/pnas.1717157115. No abstract available.

14.

Technologies to address antimicrobial resistance.

Baker SJ, Payne DJ, Rappuoli R, De Gregorio E.

Proc Natl Acad Sci U S A. 2018 Dec 18;115(51):12887-12895. doi: 10.1073/pnas.1717160115.

15.

Vision for a systems architecture to integrate and transform population health.

Madhavan G, Phelps CE, Rouse WB, Rappuoli R.

Proc Natl Acad Sci U S A. 2018 Dec 11;115(50):12595-12602. doi: 10.1073/pnas.1809919115.

16.

Vaccines: An achievement of civilization, a human right, our health insurance for the future.

Rappuoli R, Santoni A, Mantovani A.

J Exp Med. 2019 Jan 7;216(1):7-9. doi: 10.1084/jem.20182160. Epub 2018 Dec 3.

PMID:
30510147
17.

Meningococcal B vaccine (4CMenB): the journey from research to real world experience.

Rappuoli R, Pizza M, Masignani V, Vadivelu K.

Expert Rev Vaccines. 2018 Dec;17(12):1111-1121. doi: 10.1080/14760584.2018.1547637. Epub 2018 Dec 5. Review.

PMID:
30457407
18.

Comparative immunogenicity and efficacy of equivalent outer membrane vesicle and glycoconjugate vaccines against nontyphoidal Salmonella.

Micoli F, Rondini S, Alfini R, Lanzilao L, Necchi F, Negrea A, Rossi O, Brandt C, Clare S, Mastroeni P, Rappuoli R, Saul A, MacLennan CA.

Proc Natl Acad Sci U S A. 2018 Oct 9;115(41):10428-10433. doi: 10.1073/pnas.1807655115. Epub 2018 Sep 27.

19.

Glycoconjugate vaccines: Principles and mechanisms.

Rappuoli R.

Sci Transl Med. 2018 Aug 29;10(456). pii: eaat4615. doi: 10.1126/scitranslmed.aat4615. Review.

PMID:
30158151
20.

Farewell Stan Stanley Falkow: 1934-2018.

Cabello FC, Cohen SN, Curtiss R 3rd, Dougan G, van Embden J, Finlay BB, Heffron F, Helinski D, Hull R, Hull S, Isberg R, Kopecko DJ, Levy S, Mekalanos J, Ortiz JM, Rappuoli R, Roberts MC, So M, Timmis KN.

Environ Microbiol. 2018 Jul;20(7):2322-2333. doi: 10.1111/1462-2920.14308. Epub 2018 Aug 26. No abstract available.

PMID:
30146753
21.

Short-term and mid-term solutions for influenza vaccines.

Hanon E, Van der Most R, Del Giudice G, Rappuoli R.

Lancet Infect Dis. 2018 Aug;18(8):832-833. doi: 10.1016/S1473-3099(18)30404-3. No abstract available.

PMID:
30064669
22.

Efficacy, immunogenicity, and safety of a parenteral vaccine against Helicobacter pylori in healthy volunteers challenged with a Cag-positive strain: a randomised, placebo-controlled phase 1/2 study.

Malfertheiner P, Selgrad M, Wex T, Romi B, Borgogni E, Spensieri F, Zedda L, Ruggiero P, Pancotto L, Censini S, Palla E, Kanesa-Thasan N, Scharschmidt B, Rappuoli R, Graham DY, Schiavetti F, Del Giudice G.

Lancet Gastroenterol Hepatol. 2018 Oct;3(10):698-707. doi: 10.1016/S2468-1253(18)30125-0. Epub 2018 Jul 2.

PMID:
30042064
23.

Changing Priorities in Vaccinology: Antibiotic Resistance Moving to the Top.

Tagliabue A, Rappuoli R.

Front Immunol. 2018 May 30;9:1068. doi: 10.3389/fimmu.2018.01068. eCollection 2018. Review.

24.

Role of O-Acetylation in the Immunogenicity of Bacterial Polysaccharide Vaccines.

Berti F, De Ricco R, Rappuoli R.

Molecules. 2018 Jun 2;23(6). pii: E1340. doi: 10.3390/molecules23061340. Review.

25.

Correlates of adjuvanticity: A review on adjuvants in licensed vaccines.

Del Giudice G, Rappuoli R, Didierlaurent AM.

Semin Immunol. 2018 Oct;39:14-21. doi: 10.1016/j.smim.2018.05.001. Epub 2018 May 23. Review.

26.

3. How comprehensive can we be in the economic assessment of vaccines?

Standaert B, Rappuoli R.

J Mark Access Health Policy. 2017 Aug 31;5(1):1336044. doi: 10.1080/20016689.2017.1336044. eCollection 2017. Review.

27.

2. How is the economic assessment of vaccines performed today?

Standaert B, Rappuoli R.

J Mark Access Health Policy. 2017 Aug 31;5(1):1335163. doi: 10.1080/20016689.2017.1335163. eCollection 2017. Review.

28.

Towards a more comprehensive approach for a total economic assessment of vaccines?: 1. The building blocks for a health economic assessment of vaccination.

Standaert B, Rappuoli R.

J Mark Access Health Policy. 2017 Aug 31;5(1):1335162. doi: 10.1080/20016689.2017.1335162. eCollection 2017. Review.

29.

Sustainable vaccine development: a vaccine manufacturer's perspective.

Rappuoli R, Hanon E.

Curr Opin Immunol. 2018 Aug;53:111-118. doi: 10.1016/j.coi.2018.04.019. Epub 2018 May 8. Review.

30.

Human protective response induced by meningococcus B vaccine is mediated by the synergy of multiple bactericidal epitopes.

Giuliani M, Bartolini E, Galli B, Santini L, Lo Surdo P, Buricchi F, Bruttini M, Benucci B, Pacchiani N, Alleri L, Donnarumma D, Pansegrau W, Peschiera I, Ferlenghi I, Cozzi R, Norais N, Giuliani MM, Maione D, Pizza M, Rappuoli R, Finco O, Masignani V.

Sci Rep. 2018 Feb 27;8(1):3700. doi: 10.1038/s41598-018-22057-7.

31.

Deploy vaccines to fight superbugs.

Rappuoli R, Bloom DE, Black S.

Nature. 2017 Dec 14;552(7684):165-167. doi: 10.1038/d41586-017-08323-0. No abstract available.

PMID:
29239371
32.

Will Systems Biology Deliver Its Promise and Contribute to the Development of New or Improved Vaccines? Systems Biology Views of Vaccine Innate and Adaptive Immunity.

Rappuoli R, Siena E, Finco O.

Cold Spring Harb Perspect Biol. 2018 Aug 1;10(8). pii: a029256. doi: 10.1101/cshperspect.a029256. Review.

PMID:
29038117
33.

Improving accountability in vaccine decision-making.

Timmis JK, Black S, Rappuoli R.

Expert Rev Vaccines. 2017 Nov;16(11):1057-1066. doi: 10.1080/14760584.2017.1382358. Epub 2017 Oct 9. Review.

PMID:
28929818
34.

Editorial overview: Preventive and therapeutic vaccines: Vaccination against viral disease - current advances and challenges.

Rappuoli R, Sutter G.

Curr Opin Virol. 2017 Apr;23:vi-viii. doi: 10.1016/j.coviro.2017.06.001. No abstract available.

PMID:
28622999
35.

An unwanted guest: Neisseria meningitidis - carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence.

Gianchecchi E, Piccini G, Torelli A, Rappuoli R, Montomoli E.

Expert Rev Anti Infect Ther. 2017 Jul;15(7):689-701. doi: 10.1080/14787210.2017.1333422. Epub 2017 May 29. Review.

PMID:
28524748
36.

Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis.

Nascimento IP, Rodriguez D, Santos CC, Amaral EP, Rofatto HK, Junqueira-Kipnis AP, Gonçalves EDC, D'Império-Lima MR, Hirata MH, Silva CL, Winter N, Gicquel B, Mills KHG, Pizza M, Rappuoli R, Leite LCC.

Sci Rep. 2017 May 18;7(1):2109. doi: 10.1038/s41598-017-02003-9.

37.

Structure of a protective epitope of group B Streptococcus type III capsular polysaccharide.

Carboni F, Adamo R, Fabbrini M, De Ricco R, Cattaneo V, Brogioni B, Veggi D, Pinto V, Passalacqua I, Oldrini D, Rappuoli R, Malito E, Margarit IYR, Berti F.

Proc Natl Acad Sci U S A. 2017 May 9;114(19):5017-5022. doi: 10.1073/pnas.1701885114. Epub 2017 Apr 24.

38.

Emerging infectious diseases: A proactive approach.

Bloom DE, Black S, Rappuoli R.

Proc Natl Acad Sci U S A. 2017 Apr 18;114(16):4055-4059. doi: 10.1073/pnas.1701410114. Epub 2017 Apr 10.

39.

Emerging experience with meningococcal serogroup B protein vaccines.

Toneatto D, Pizza M, Masignani V, Rappuoli R.

Expert Rev Vaccines. 2017 May;16(5):433-451. doi: 10.1080/14760584.2017.1308828. Epub 2017 Apr 10. Review.

PMID:
28375029
40.

Vaccines for Staphylococcus aureus and Target Populations.

Pozzi C, Olaniyi R, Liljeroos L, Galgani I, Rappuoli R, Bagnoli F.

Curr Top Microbiol Immunol. 2017;409:491-528. doi: 10.1007/82_2016_54.

PMID:
28197738
41.

Meningococcal B Vaccine during a University Outbreak.

Rappuoli R.

N Engl J Med. 2016 Oct 20;375(16):1594-5. doi: 10.1056/NEJMc1610666. No abstract available.

PMID:
28103429
42.

Compare voting systems to improve them.

Madhavan G, Phelps C, Rappuoli R.

Nature. 2017 Jan 10;541(7636):151-153. doi: 10.1038/541151a. No abstract available.

PMID:
28079088
43.

Core values for vaccine evaluation.

Timmis JK, Rigat F, Rappuoli R.

Vaccine. 2017 Jan 20;35 Suppl 1:A57-A62. doi: 10.1016/j.vaccine.2016.11.034. Epub 2016 Dec 22.

PMID:
28017445
44.

Introduction to the vaccine supplement.

Rappuoli R.

Vaccine. 2017 Jan 20;35 Suppl 1:A1. doi: 10.1016/j.vaccine.2016.11.038. Epub 2016 Dec 22. No abstract available.

PMID:
28017437
45.

Beyond cost-effectiveness: Using systems analysis for infectious disease preparedness.

Phelps C, Madhavan G, Rappuoli R, Colwell R, Fineberg H.

Vaccine. 2017 Jan 20;35 Suppl 1:A46-A49. doi: 10.1016/j.vaccine.2016.08.090. Epub 2016 Dec 22.

PMID:
28017432
46.

Comparative Systems Analyses Reveal Molecular Signatures of Clinically tested Vaccine Adjuvants.

Olafsdottir TA, Lindqvist M, Nookaew I, Andersen P, Maertzdorf J, Persson J, Christensen D, Zhang Y, Anderson J, Khoomrung S, Sen P, Agger EM, Coler R, Carter D, Meinke A, Rappuoli R, Kaufmann SH, Reed SG, Harandi AM.

Sci Rep. 2016 Dec 13;6:39097. doi: 10.1038/srep39097.

47.

Editorial overview: Vaccines: novel technologies for vaccine development.

Rappuoli R, De Gregorio E.

Curr Opin Immunol. 2016 Aug;41:v-vii. doi: 10.1016/j.coi.2016.07.001. Epub 2016 Aug 4. No abstract available.

PMID:
27499109
48.

Novel adjuvant Alum-TLR7 significantly potentiates immune response to glycoconjugate vaccines.

Buonsanti C, Balocchi C, Harfouche C, Corrente F, Galli Stampino L, Mancini F, Tontini M, Malyala P, Bufali S, Baudner B, De Gregorio E, Valiante NM, O'Hagan DT, Rappuoli R, D'Oro U.

Sci Rep. 2016 Jul 21;6:29063. doi: 10.1038/srep29063.

49.

Multicriteria decision analysis and core values for enhancing vaccine-related decision-making.

Barocchi MA, Black S, Rappuoli R.

Sci Transl Med. 2016 Jun 29;8(345):345ps14. doi: 10.1126/scitranslmed.aaf0756. Review.

PMID:
27358496
50.

Future Challenges for Vaccinologists.

Thomas S, Dilbarova R, Rappuoli R.

Methods Mol Biol. 2016;1403:41-55. doi: 10.1007/978-1-4939-3387-7_2.

PMID:
27076124

Supplemental Content

Loading ...
Support Center